Spinal Muscular Atrophy Type 3 Clinical Trials

Find Spinal Muscular Atrophy Type 3 Clinical Trials Near You

Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Type (CMT1B), 2A (CMT2A), 4A (CMT4A), 4C (CMT4C), and Others

Status: Recruiting
Location: See all (24) locations...
Study Type: Observational
SUMMARY

This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

⁃ General Criteria

⁃ 1\. All patients must agree to take part in the study and sign a consent form. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).

⁃ Patients:

• Must have a documented, disease-causing variant(s) in a gene with a known or preliminary association with CMT gene as per Strande et al. 2017 AND consistent with the inheritance pattern associated with the genetic subtype (heterozygous in autosomal dominant, biallelic in autosomal recessive, hemizygous males with X-linked).

• OR have a first- or second-degree family member (parent, child, sibling, half-sibling, aunt, uncle, grandparent, or grandchild) with a documented disease-causing variant(s) as above AND a clear link between that family member and the affected patient AND a phenotype consistent with the diagnosis.

• In cases where clear links are not available, genetic confirmation is required.

• Patients who have a variant(s) of uncertain significance on clinical laboratory reports may still be included if:

• The variant is categorized as pathogenic or likely pathogenic per the Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. (Richards et al., 2015)

• OR the variant has been found in multiple affected people in a family and has not been found in unaffected family members per ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classification. (Biesecker et al. 2023)

• OR the principal investigator and the site investigator agree that the variant(s) is (are) likely disease-causing.

⁃ Controls

• Must not have a peripheral neuropathy, as determined by the site investigator.

• Must have understood and signed an IRB approved consent form for the study. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).

Locations
United States
California
Cedars-Sinai Medical Center
RECRUITING
Los Angeles
Stanford University
RECRUITING
Palo Alto
Colorado
University of Colorado Hospital
RECRUITING
Aurora
Connecticut
University of Connecticut/Connecticut Children's Medical Center
RECRUITING
Hartford
Florida
University of Miami
RECRUITING
Miami
Iowa
University of Iowa
RECRUITING
Iowa City
Massachusetts
Harvard/Massachusetts General Hospital
RECRUITING
Boston
Maryland
Johns Hopkins University
RECRUITING
Baltimore
Michigan
University of Michigan
RECRUITING
Ann Arbor
Minnesota
University of Minnesota
RECRUITING
Minneapolis
North Carolina
University of North Carolina
RECRUITING
Chapel Hill
New York
University of Rochester
RECRUITING
Rochester
Ohio
Nationwide Children's Hospital
RECRUITING
Columbus
Pennsylvania
Children's Hospital of Philadelphia
RECRUITING
Philadelphia
University of Pennsylvania
RECRUITING
Philadelphia
Tennessee
St. Jude Children's Research Hospital
RECRUITING
Memphis
Texas
Houston Methodist Hospital
RECRUITING
Houston
Washington
Seattle Children's Hospital
RECRUITING
Seattle
Other Locations
Australia
University of Westmead
RECRUITING
Sydney
Canada
The Hospital for Sick Children
RECRUITING
Toronto
Cyprus
The Cyprus Institute of Neurology & Genetics
RECRUITING
Nicosia
Italy
C. Besta Neurological Institute
RECRUITING
Milan
United Kingdom
Great Ormond Street Hospital
RECRUITING
London
National Hospital of Neurology and Neurosurgery
RECRUITING
London
Contact Information
Primary
Nicole M Kressin, MSN, RN
UICMTClinic@uiowa.edu
319-384-6362
Backup
Tiffany Grider, MS, CGC
UICMTClinic@uiowa.edu
319-384-6362
Time Frame
Start Date: 2010-04-01
Estimated Completion Date: 2030-12
Participants
Target number of participants: 5000
Treatments
CMT1B
Families/patients with genetically confirmed CMT1B
CMT2A
Families/patients with genetically confirmed CMT2A
CMT4A
Families/patients with genetically confirmed CMT4A
CMT4C
Families/patients with genetically confirmed CMT4C
All other CMT
Families/patients with all other forms of CMT or CMT that has not yet been genetically identified
Sponsors
Collaborators: University of Rochester, King's College Hospital NHS Trust, Stanford University, University of Miami, Massachusetts General Hospital, Children's Hospital of Philadelphia, Muscular Dystrophy Association, Sydney Children's Hospitals Network, University of Minnesota, National Institute of Neurological Disorders and Stroke (NINDS), Dubowitz Neuromuscular Centre, University of Pennsylvania, Charcot-Marie-Tooth Association, Cedars-Sinai Medical Center, National Hospital for Neurology and Neurosurgery, Rare Diseases Clinical Research Network, Johns Hopkins University, National Institutes of Health (NIH), Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, University of Colorado, Denver, Connecticut Children's Medical Center
Leads: Michael Shy

This content was sourced from clinicaltrials.gov